(Q53245652)

12 May 2018

title

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. (English)

1 reference

12 May 2018

4

Cheolwon Suh

1 reference

12 May 2018

author name string

Young Wha Koh

1

1 reference

12 May 2018

Yoon Kyung Jeon

2

1 reference

12 May 2018

Dok Hyun Yoon

3

1 reference

12 May 2018

Jooryung Huh

5

1 reference

12 May 2018

publication date

17 December 2015

1 reference

12 May 2018

published in

Tumor Biology

1 reference

12 May 2018

volume

37

1 reference

12 May 2018

issue

6

1 reference

12 May 2018

page(s)

7507-7514

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1007/s13277-015-4622-5

exact match

0 references

cites work

Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Salvage therapy for Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PDL1 expression is an independent prognostic factor in localized GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Programmed death ligand 2 in cancer-induced immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

A review of human carcinogens--Part B: biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

21 January 2018

PD-1/PD-L1 inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4622-5

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26678894

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26678894

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-015-4622-5

1 reference

12 May 2018

PubMed ID

26678894

1 reference

12 May 2018